Zynex, Inc. (NASDAQ: ZYXI) reported Q1 EPS of $0.07, $0.02 better than the analyst estimate of $0.05. Revenue for the quarter came in at $9.2 million versus the consensus estimate of $8.49 million.

President and CEO Commentary:Thomas Sandgaard, CEO said: "We started 2019 strong with revenue of $9.2 million in the first quarter and net income of $2.4 million. Orders grew 30% compared to the first quarter of 2018 and were 4% higher than the fourth quarter of 2018."

"In the first quarter, we continued to aggressively expand our sales force. We expect the addition of new sales reps to have an impact on order and revenue growth this year and going forward."

"We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."

GUIDANCE:

Zynex, Inc. sees Q2 2019 revenue of $9.5-10 million, versus the consensus of $9.4 million.

For earnings history and earnings-related data on Zynex, Inc. (ZYXI) click here.